Voltaren and Peripheral vascular disorder - a phase IV clinical study of FDA data

Summary:

Peripheral vascular disorder is reported as a side effect among people who take Voltaren (diclofenac sodium), especially for people who are female, 60+ old, have been taking the drug for < 1 month also take Lipitor, and have Primary myelofibrosis.

The phase IV clinical study analyzes which people have Peripheral vascular disorder when taking Voltaren. It is created by eHealthMe based on reports of 81,356 people who have side effects when taking Voltaren from the FDA, and is updated regularly.

What is Voltaren?

Voltaren has active ingredients of diclofenac sodium. It is often used in arthritis. eHealthMe is studying from 82,346 Voltaren users. Check the latest studies of Voltaren.

What is Peripheral vascular disorder?

Peripheral vascular disorder is found to be associated with 783 drugs and 758 conditions by eHealthMe. Check the latest studies of Peripheral vascular disorder.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Aug, 26, 2026

81,356 people reported to have side effects when taking Voltaren.
Among them, 62 people (0.08%) have Peripheral vascular disorder.

Could Voltaren cause Peripheral vascular disorder?

Among these 62 people:

How long have people been on Voltaren when they have Peripheral vascular disorder? *

What is the gender of people who have Peripheral vascular disorder when taking Voltaren? *

female: 74.55 %
male: 25.45 %

What is the age of people who have Peripheral vascular disorder when taking Voltaren? *

What are other drugs people take besides Voltaren? *

What are other side effects people have besides Peripheral vascular disorder? *

Joint Pain: 32 people, 51.61%
Anaemia (lack of blood): 29 people, 46.77%
Pain In Extremity: 29 people, 46.77%
Fatigue (feeling of tiredness): 26 people, 41.94%
Itching: 21 people, 33.87%
Muscle Spasms (muscle contraction): 21 people, 33.87%
Thrombocytopenia (decrease of platelets in blood): 20 people, 32.26%
Stroke (sudden death of a portion of the brain cells due to a lack of oxygen): 20 people, 32.26%
Nausea And Vomiting: 18 people, 29.03%
Atherosclerosis (disorder of the arteries): 18 people, 29.03%

What are the existing conditions these people have? *

Primary Myelofibrosis (primary disorder of the bone marrow): 14 people, 22.58%
Osteoporosis (bones weak and more likely to break): 10 people, 16.13%
Gastroesophageal Reflux Disease (a condition in which stomach contents leak backward from the stomach into the oesophagus): 10 people, 16.13%
Rheumatoid Arthritis (a chronic progressive disease causing inflammation in the joints): 9 people, 14.52%
Hyperlipidaemia (presence of excess lipids in the blood): 7 people, 11.29%
Gravitational Oedema (abnormally large fluid volume in the circulatory system makes obese): 7 people, 11.29%
Menopause (end of monthly cycles in women): 6 people, 9.68%
Thyroid Diseases: 5 people, 8.06%
Bone Density Decreased: 4 people, 6.45%
High Blood Cholesterol: 4 people, 6.45%

* Approximation only. Some reports may have incomplete information.

Do you take Voltaren and have Peripheral vascular disorder?

- Check whether Peripheral vascular disorder is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Voltaren:

Voltaren (82,346 reports)

Browse all side effects of Voltaren:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Peripheral vascular disorder:

Peripheral vascular disorder (783 drugs)

Browse all the conditions that are associated with Peripheral vascular disorder:

Peripheral vascular disorder (758 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on diclofenac sodium (the active ingredients of Voltaren) and Voltaren (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.